



May 19, 2021

Initiatives Against COVID-19 in Canada - Achieved Positive Interim Phase 2 Results for adjuvanted COVID-19 vaccine candidate -

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President & Representative Director; Hiroaki Ueno) announced today that its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; President; Takashi Nagao) and GlaxoSmithKline (Head Office: London, United Kingdom; hereafter, "GSK") jointly announced on May 18 local time positive interim Phase 2 clinical trial results for its plant-derived virus-like particle (VLP) vaccine candidate in combination with GSK's adjuvant (project code: MT-2766) for the prevention of COVID-19 which has been developing by Medicago.

The following are the summary and interim results of Phase 2 clinical trial. These results are part of the ongoing Phase 2/3 study.

- **Subjects:** Healthy adults (18y to 64y), elderly adults (65y+) in Canada and the United States, each age group enrolled up to 306 subjects.
- **Dosage and administration:** Two doses of 3.75µg VLP vaccine candidate combined with GSK's adjuvant given 21 days apart.
- **Endpoints:** Immunogenicity and safety
- **Interim results:** Similar antibody response in adults and in the elderly after two doses. Neutralizing antibody responses were 10 times higher than people recovering from COVID-19 disease. No severe adverse events were observed.

Phase 3 trial is currently ongoing in Canada, the US, the UK, and Brazil with additional sites expected to be added in the coming weeks, with enrolling up to 30,000 subjects.

Mitsubishi Tanabe Pharma Group will work to develop MT-2766 and deliver VLP vaccines to society as soon as possible, contributing even further to the prevention of COVID-19, a pressing social issue.

Medicago release (May 18, 2021, local time)

[Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate](#)

Mitsubishi Tanabe Pharma Corporation
Communication Crossroads Department

Media contacts: TEL:+81 6 6205 5119